Fujisawa plans expansion of reagent sales:
This article was originally published in Clinica
Executive Summary
Fujisawa (Japan) has reported diagnostic reagent sales for 1994 of approximately ¥,700 million ($17 million), according to Japan Medical Review (October). Although reagents currently account for less than 1% of Fujisawa's overall turnover, the company is aiming at "aggressive" development of this market. Under a recent distribution deal concluded with US company Vysis (see Clinica No 667, p 9), Fujisawa will start marketing a Vysis genetic analysis kit in Japan later this year.